Abdelwahab Yousef AJ. Male breast cancer: epidemiology and risk factors. Semin Oncol. 2017;44:267–72.
Giordano SH, Buzdar AU, Hortobagyi GN. Breast cancer in men. Ann Intern Med. 2002;137:678–87.
Chen T, Fallah M, Jansen L, Castro FA, Krilavicuite A, Katalinic A, et al. Distribution and risk of the second discordant primary cancers combined after a specific first primary cancer in German and Swedish cancer registries. Cancer Lett. 2015;369:152–66.
Jégu J, Colonna M, Daubisse-Marliac L, Trétarre B, Ganry O, Guizard AV, et al. The effect of patient characteristics on second primary cancer risk in France. BMC Cancer. 2014;14:94.
Hemminki K, Scélo G, Boffetta P, Mellemkjaer L, Tracey E, Andersen A, et al. Second primary malignancies in patients with male breast cancer. Br J Cancer. 2005;92:1288–92.
AIRTUM Working Group. Italian cancer figures, report 2013: multiple tumours. Epidemiol Prev. 2013;37(4–5 Suppl 1):1–152.
Hung MH, Liu CJ, Teng CJ, Hu YW, Yeh CM, Chen SC, et al. Risk of second non-breast primary cancer in male and female breast cancer patients: a population-based cohort study. PLoS ONE. 2016;11:e0148597.
Satram-Hoang S, Ziogas A, Anton-Culver H. Risk of second primary cancer in men with breast cancer. Breast Cancer Res. 2007;9:R10.
Dong C, Hemminki K. Second primary neoplasms in 633,964 cancer patients in Sweden, 1958-1996. Int J Cancer. 2001;93:155–61.
Auvinen A, Curtis RE, Ron E. Risk of subsequent cancer following breast cancer in men. J Natl Cancer Inst. 2002;94:1330–2.
Mangone L, Ferrari F, Mancuso P, Carrozzi G, Michiara M, Falcini F, et al. Epidemiology and biological characteristics of male breast cancer in Italy. Breast Cancer. 2020;27:724–31.
Sung H, Hyun N, Leach CR, Yabroff KR, Jemal A. Association of first primary cancer. with risk of subsequent primary cancer among survivors of adult-onset cancers in the United States. J Am Med Assoc. 2020;324:2521–35.
Wang F, Shu X, Meszoely I, Pal T, Mayer IA, Yu Z, et al. Overall mortality after diagnosis of breast cancer in men vs women. JAMA Oncol. 2019;5:1589–96.
Pizzato M, Carioli G, Bertuccio P, Malvezzi M, Levi F, Boffetta P, et al. Trends in male breast cancer mortality: a global overview. Eur J Cancer Prev. 2021;30:472–9.
Grenader T, Goldberg A, Shavit L. Second cancers in patients with male breast cancer: a literature review. J Cancer Surviv. 2008;2:73–8.
Adamo M, Groves C, Dickie L, Ruhl J. SEER program coding and staging manual 2021. National Cancer Institute, Bethesda, MD 20892: U.S. Department of Health and Human Services National Institutes of Health National Cancer Institute; 2021.
Coyte A, Morrison DS, McLoone P. Second primary cancer risk—the impact of applying different definitions of multiple primaries: results from a retrospective population-based cancer registry study. BMC Cancer. 2014;14:272.
Working Group Report. International rules for multiple primary cancers (ICD-0 third edition). Eur J Cancer Prev. 2005;14:307–8.
International Association of Cancer Registries. International rules for multiple primary cancers. Asian Pac J Cancer Prev. 2005;6:104–6.
Weir HK, Johnson CJ, Ward KC, Coleman MP. The effect of multiple primary rules on cancer incidence rates and trends. Cancer Causes Control. 2016;27:377–90.
Hemminki K, Ji J, Brandt A, Mousavi SM, Sundquist J. The Swedish family-cancer database 2009: prospects for histology-specific and immigrant studies. Int J Cancer. 2010;126:2259–67.
R Core Team. R: A language and environment for statistical computing. Vienna, Austria: R Foundation for Statistical Computing. 2021. https://www.R-project.org/.
Higgins J, Green S. Cochrane handbook for systematic reviews of interventions. Chichester (UK): Wiley; 2019.
DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials. 1986;7:177–88.
Breslow NE, Day NE. Statistical methods in cancer research. Volume II-The design and analysis of cohort studies. IARC Sci Publ. 1987;2:1–406.
Cancer Research UK. Cancer incidence for common cancers. https://www.cancerresearchuk.org/health-professional/cancer-statistics/incidence/common-cancers-compared#heading-Zero, 2021.
Cooper H, Hedges LV. The handbook of research synthesis. New York: Russell Sage Foundation; 1994.
Higgins JPT, Thompson SG. Quantifying heterogeneity in a meta-analysis. Stat Med. 2002;21:1539–58.
Higgins JPT, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. BMJ. 2003;327:557–60.
Egger M, Davey Smith G, Schneider M, Minder C. Bias in meta-analysis detected by a simple, graphical test. BMJ. 1997;315:629–34.
Harrer M, Cuijpers P, Furukawa TA, Ebert DD. Doing meta-analysis with R. Boca Raton: Chapman and Hall/CRC; 2021.
Wells G, Shea B, O’Connell D, Peterson J, Welch V, Losos M, et al. The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomised studies in meta-analyses. http://www.ohri.ca/programs/clinical_epidemiology/oxford.asp, 2012.
Molina-Montes E, Requena M, Sánchez-Cantalejo E, Fernández MF, Arroyo-Morales M, Espín J, et al. Risk of second cancers cancer after a first primary breast cancer: a systematic review and meta-analysis. Gynecol Oncol. 2015;136:158–71.
Kao WH, Hong JH, See LC, Yu HP, Hsu JT, Chou IJ, et al. Validity of cancer diagnosis in the National Health Insurance database compared with the linked National Cancer Registry in Taiwan. Pharmacoepidemiol Drug Saf. 2018;27:1060–6.
Li S, Silvestri V, Leslie G, Rebbeck TR, Neuhausen SL, Hopper JL, et al. Cancer risks associated with BRCA1 and BRCA2 pathogenic variants. J Clin Oncol. 2022;40:JCO2102112.
Liede A, Karlan BY, Narod SA. Cancer risks for male carriers of germline mutations in BRCA1 or BRCA2: a review of the literature. J Clin Oncol. 2004;22:735–42.
Pritzlaff M, Summerour P, McFarland R, Li S, Reineke P, Dolinsky JS, et al. Male breast cancer in a multi-gene panel testing cohort: insights and unexpected results. Breast Cancer Res Treat. 2017;161:575–86.
Yang X, Leslie G, Doroszuk A, Schneider S, Allen J, Decker B, et al. Cancer risks associated with germline PALB2 pathogenic variants: an international study of 524 families. J Clin Oncol. 2020;38:674–85.
Nielsen SM, White MG, Hong S, Aschebrook-Kilfoy B, Kaplan EL, Angelos P, et al. The breast-thyroid cancer link: a systematic review and meta-analysis. Cancer Epidemiol Biomark Prev. 2016;25:231–8.
Bazire L, de Rycke Y, Asselain B, Fourquet A, Kirova YM. Risks of second malignancies after breast cancer treatment: Long-term results. Cancer Radiotherapie: J de la Soc francaise de radiotherapie oncologique. 2017;21:10–5.
Kirova YM, de Rycke Y, Gambotti L, Pierga JY, Asselain B, Fourquet A, et al. Second malignancies after breast cancer: the impact of different treatment modalities. Br J Cancer. 2008;98:870–4.
Murakami R, Hiyama T, Hanai A, Fujimoto I. Second primary cancers following female breast cancer in Osaka, Japan-a population-based cohort study. Jpn J Clin Oncol. 1987;17:293–302.
Liang M, Zhang Y, Sun C, Rizeq FK, Min M, Shi T, et al. Association between CHEK2*1100delC and breast cancer: a systematic review and meta-analysis. Mol Diagn Ther. 2018;22:397–407.
de Jong MM, Nolte IM, te Meerman GJ, van der Graaf WTA, Mulder MJ, van der Steege G, et al. Colorectal cancer and the CHEK2 1100delC mutation. Genes Chromosomes Cancer. 2005;43:377–82.
Cybulski C, Wokołorczyk D, Kładny J, Kurzawski G, Kurzwaski G, Suchy J, et al. Germline CHEK2 mutations and colorectal cancer risk: different effects of a missense and truncating mutations? Eur J Hum Genet. 2007;15:237–41.
Oh M, Alkhushaym N, Fallatah S, Althagafi A, Aljadeed R, Alsowaida Y, et al. The association of BRCA1 and BRCA2 mutations with prostate cancer risk, frequency, and mortality: a meta-analysis. Prostate 2019;79:880–95.
Southey MC, Goldgar DE, Winqvist R, Pylkäs K, Couch F, Tischkowitz M, et al. PALB2, CHEK2 and ATM rare variants and cancer risk: data from COGS. J Med Genet. 2016;53:800–11.
Seppälä EH, Ikonen T, Mononen N, Autio V, Rökman A, Matikainen MP, et al. CHEK2 variants associate with hereditary prostate cancer. Br J Cancer. 2003;89:1966–70.
Dong X, Wang L, Taniguchi K, Wang X, Cunningham JM, McDonnell SK, et al. Mutations in CHEK2 associated with prostate cancer risk. Am J Hum Genet. 2003;72:270–80.
Schlebusch CM, Dreyer G, Sluiter MD, Yawitch TM, van den Berg HJ, van Rensburg EJ. Cancer prevalence in 129 breast-ovarian cancer families tested for BRCA1 and BRCA2 mutations. S Afr Med J. 2010;100:113–7.
Teodorczyk U, Cybulski C, Wokołorczyk D, Jakubowska A, Starzyńska T, Lawniczak M, et al. The risk of gastric cancer in carriers of CHEK2 mutations. Fam Cancer. 2013;12:473–8.
Kuchenbaecker KB, Hopper JL, Barnes DR, Phillips KA, Mooij TM, Roos-Blom MJ, et al. Risks of breast, ovarian, and contralateral breast cancer for BRCA1 and BRCA2 mutation carriers. J Am Med Assoc. 2017;317:2402–16.
Silva SN, Gomes BC, André S, Félix A, Rodrigues AS, Rueff J. Male and female breast cancer: the two faces of the same genetic susceptibility coin. Breast Cancer Res Treat. 2021;188:295–305.
Bevier M, Sundquist K, Hemminki K. Risk of breast cancer in families of multiple affected women and men. Breast Cancer Res Treat. 2012;132:723–8.
de Sanjosé S, Léoné M, Bérez V, Izquierdo A, Font R, Brunet JM, et al. Prevalence of BRCA1 and BRCA2 germline mutations in young breast cancer patients: a population-based study. Int J Cancer. 2003;106:588–93.
Haffty BG, Choi DH, Goyal S, Silber A, Ranieri K, Matloff E, et al. Breast cancer in young women (YBC): prevalence of BRCA1/2 mutations and risk of secondary malignancies across diverse racial groups. Ann Oncol. 2009;20:1653–9.
Cao AY, Huang J, Hu Z, Li WF, Ma ZL, Tang LL, et al. The prevalence of PALB2 germline mutations in BRCA1/BRCA2 negative Chinese women with early onset breast cancer or affected relatives. Breast Cancer Res Treat. 2009;114:457–62.
Ademuyiwa FO, Cyr A, Ivanovich J, Thomas MA. Managing breast cancer in younger women: challenges and solutions breast. Cancer. 2016;8:1–12.
Radosa JC, Eaton A, Stempel M, Khander A, Liedtke C, Solomayer EF, et al. Evaluation of local and distant recurrence patterns in patients with triple-negative breast cancer according to age. Ann Surg Oncol. 2017;24:698–704.
Hemminki K, Hemminki O, Försti A, Sundquist K, Sundquist J, Li X. Surveillance bias in cancer risk after unrelated medical conditions: example urolithiasis. Sci Rep. 2017;7:8073.
